Skip to content
DataLookout
Menu

ADOPTpilotNCT06698510

Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 6 words Show 7 more changesShow less
    • Trial completed
    • Final enrollment: 13118 participants (planned 18500)
    • Primary completion date changed from estimate of Nov 2025 to Apr 1, 2025
    • Study completion date changed from estimate of Mar 2026 to Oct 30, 2025
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised at 7 of 7 sites
    • Collaborators revised (9)
  2. Minor Primary completion date: Jun 2025 to Nov 2025
    • Study completion date: Jan 2026 to Mar 2026
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2024 to Nov 25, 2024
    • Site details revised at 7 of 7 sites
    • Collaborators revised (9)
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Platform performance for arPZQ distribution
Timeframe: Documentation from 3 months before up to 12 weeks after the drug distribution

Secondary (1)

Effectiveness of social mobilization, communication and training

Arms and interventions

arPZQ distributed through Platform 1 (NTD programmes)

Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg/kg or 60mg/kg (depending on country) arpraziquantel as part of the routine schistosomiasis mass drug administration campaigns led by the national NTD programmes.

arPZQ distributed through Platform 2 (child health days/nutrition programmes)

Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg/kg or 60mg/kg (depending on country) arpraziquantel as part of the routine vitamin A distribution/child health days campaigns led by the national nutrition programmes.

Drugs: Arpraziquantel 150mg dispersible tablet

Sites

7 sites in 3 countries

Côte d’Ivoire 3, Kenya 2, Uganda 2